Metagenomi Stock (NASDAQ:MGX)


ForecastRevenueFinancialsChart

Previous Close

$4.05

52W Range

$1.61 - $12.74

50D Avg

$2.31

200D Avg

$4.77

Market Cap

$150.07M

Avg Vol (3M)

$1.79M

Beta

-

Div Yield

-

MGX Company Profile


Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

236

IPO Date

Apr 06, 2006

Website

MGX Performance


MGX Financial Summary


Dec 23Dec 22Dec 21
Revenue$44.76M$17.20M$243.00K
Operating Income$-78.49M$-44.64M$-23.95M
Net Income$-68.25M$-43.59M$-21.44M
EBITDA$-58.89M$-39.29M$-23.51M
Basic EPS$-1.82$-1.45$-0.72
Diluted EPS$-1.82$-1.45$-0.72

Fiscal year ends in Dec 23 | Currency in USD